EGFR-activating mutations are observed in approximately 15% to 20% of patients with non–
small cell lung cancer. Tyrosine kinase inhibitors have provided an illustrative example of …

Before the introduction of tyrosine kinase inhibitors (TKIs) for a particular subgroup of
patients, despite platinum-based combination chemotherapy, the majority of patients …

Lung cancer, of which non-small lung cancer is the most common subtype, represents the
leading cause of cancer related-death worldwide. It is now recognized that a significant …

The treatment of advanced non-small cell lung cancer (NSCLC) has evolved substantially
during the last years. Chemotherapy remains the cornerstone of treatment and prolongs …

Lung cancer remains the number one cause of cancer-related deaths worldwide with
221,200 estimated new cases and 158,040 estimated deaths in 2015. Approximately 80% of …

Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are a frequent
class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial …

In recent years there has been undoubted progress in the evaluation and development of
targeted agents for non-small cell lung cancer (NSCLC). A major contributor has been the …

Non-small cell lung cancer (NSCLC) tumours with certain mutations in the epidermal growth
factor receptor (EGFR) tyrosine kinase have been termed 'oncogene addicted'to reflect their …